On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
ORGANIZATION
Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
Tohoku University’s Tohoku Medical Megabank Organization (ToMMo) and the Japan Pharmaceutical Manufacturers Association (JPMA) have kicked off joint research aimed at bringing preventive and preemptive medicine into practical use as early as possible, they said on March 31. The partners…
To read the full story
Related Article
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
- JPMA, Tohoku Medical Megabank to Start Collaborative Research on Preemptive Health
January 30, 2020
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
ORGANIZATION
- Bayer Yakuhin President Heike Prinz Elected New EFPIA Japan Chief
August 3, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
July 21, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…